GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

England’s cost effectiveness body NICE has recommended GSK’s new severe asthma treatment Nucala, reversing an earlier decision to reject it. Nucala (mepolizumab) is the first biologic ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...